EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mankind Pharma's enterprise value is ₹878,683 Mil.
Mankind Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹21,455 Mil. Therefore, Mankind Pharma's EV-to-EBITDA for today is 40.95.
The historical rank and industry rank for Mankind Pharma's EV-to-EBITDA or its related term are showing as below:
BOM:543904'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 26.71 Med: 31.2 Max: 40.96
Current: 40.96
During the past 3 years, the highest EV-to-EBITDA of Mankind Pharma was 40.96. The lowest was 26.71. And the median was 31.20.
BOM:543904's EV-to-EBITDA is ranked worse than 87.23% of 705
companies
in the Drug Manufacturers industry
Industry Median: 14.58
vs BOM:543904: 40.96
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Mankind Pharma EV-to-EBITDA Historical Data
The historical data trend for Mankind Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mankind Pharma's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mankind Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mankind Pharma's EV-to-EBITDA falls into.
Mankind Pharma EV-to-EBITDA Calculation
Mankind Pharma's EV-to-EBITDA for today is calculated as:
Mankind Pharma's current Enterprise Value is ₹878,683 Mil.
Mankind Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹21,455 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Mankind Pharma's PE Ratio for today is calculated as:
Mankind Pharma's share price for today is ₹2247.45.
Mankind Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹35.954.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Mankind Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Mankind Pharma Ltd is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News and Gas-O-Fast.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:543904 has been successfully added to your 